Common use of Use of the Material Clause in Contracts

Use of the Material. 2.1 The Recipient shall use the Material in compliance with all laws and regulations applicable to such Material in the Recipient's place and country, including guidelines for work with recombinant DNA. The Material being experimental in nature must not be used in humans or animals unless -where applicable -explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals. 2.2 Nothing in this agreement shall be construed as granting any license under any intellectual property right vested into EMBL or any right to use the Material or any EMBL information other than herein expressly specified. The Material shall be used exclusively for the purposes described in Annex 1. It must not be released to any person other than the Recipient's Researcher/s named above and staff under their direct supervision who are bound by obligations not less strict than those set out herein. It shall be handled confidentially and forwarded to third parties only to the extent of EMBL’s prior written approval. The Recipient shall not use the Material or any substance that is replicated or derived thereof for any commercial or profit-generating purpose, or in the conduct of research that is subject to consulting, licensing or other similar legal or commercial obligations with other institutions, corporations or business entities including, but not limited to, use in drug screening, drug evaluation, assay development, or identifying drug targets for commercial purposes without the prior written consent of EMBL. 2.3 After conclusion of the studies using the Material as defined in Annex 1 or at the expiry of this MTA, whichever occurs first, the Recipient shall, at the discretion of the EMBL, either destroy or return to the EMBL the remaining Material and Modifications incorporating the Material. Upon request, the Recipient shall inform EMBL on the status of its research.

Use of the Material. 2.1 The Recipient represents and warrants that it shall only use the Material for the purpose of the Project in order to make the research specifically described in Annex 2 to this Agreement. The Recipient agrees that it shall not be entitled to use, perform tests and / or carry out any other analysis of the Material nor any of its analogs, derivatives, synthesis or mixture of compounds for purposes not described in Annex 2, by itself or through third parties. The Recipient agrees not to make, develop, use, carry out tests and / or analyze the Material in any way for commercial purposes. The Material shall not be used in research under consulting or license agreements of the Recipient or its scientific and / or employees with individuals, companies or other institutions not bound by this Agreement, without the prior written consent of the Provider. The Recipient represents and warrants that it will use the Material in compliance with all applicable laws and regulations applicable to such Material in the Recipient's place and countryregulations, including guidelines for work with recombinant DNAbut not limited to health legislation relating to research involving the use of animals. The Material being experimental in nature must not be used in humans or animals unless -where applicable -explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals. 2.2 Nothing in this agreement shall be construed as granting any license under any intellectual property right vested into EMBL or any right to use Parties agree that the Material or any EMBL information other than herein expressly specifiedSHALL NOT BE USED IN HUMANS. The Material shall be stored and used exclusively for only at the purposes described in Annex 1. It must premises of the Recipient who undertakes not be released to any person other than change the Recipient's Researcher/s named above and staff under their direct supervision who are bound by obligations not less strict than those set out herein. It shall be handled confidentially and forwarded to third parties only to the extent location of EMBL’s prior written approval. The Recipient shall not use the Material or any substance that is replicated or derived thereof for any commercial or profit-generating purpose, or in the conduct custody of research that is subject to consulting, licensing or other similar legal or commercial obligations with other institutions, corporations or business entities including, but not limited to, use in drug screening, drug evaluation, assay development, or identifying drug targets for commercial purposes the same without the prior written consent of EMBL. 2.3 After conclusion of the studies using Provider. The Recipient also undertakes to limit access to the Material as defined to those of its employees taking part in Annex 1 or at the expiry Project who require access to the Material for the fulfilment of their responsibilities thereunder. In this MTA, whichever occurs firstregard, the Recipient shall, at ensures that all of its employees having access to Material shall comply with the discretion provisions of this Agreement. This Agreement does not restrict the right of the EMBLProvider to transfer, either destroy deliver or return distribute the Material to third parties for commercial purposes or not, or to continue their own research and development of the EMBL Materials. The present Agreement does not restrict the remaining Material and Modifications incorporating right of the Provider to publish, disclose or communicate information related to the Material. Upon request, The Recipient acknowledges that the Recipient shall inform EMBL Provider does not grant any license to commercial use of the Material and that it may grant licenses to third parties for commercial purposes on the status of its researchan exclusive or non-exclusive basis.

Use of the Material. 2.1 The Recipient shall use the Material in compliance with all laws and regulations applicable to such Material in the Recipient's place and country, including guidelines for work with recombinant DNA. The Material being experimental in nature must not be used in humans or animals unless -where applicable -explicitly - explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals. 2.2 Nothing in this agreement shall be construed as granting any license under any intellectual property right vested into EMBL or any right to use the Material or any EMBL information other than herein expressly specified. The Material shall be used exclusively for the purposes described in Annex 1. It must not be released to any person other than the Recipient's Researcher/s named above and staff under their direct supervision who are bound by obligations not less strict than those set out herein. It shall be handled confidentially and forwarded to third parties only to the extent of EMBL’s prior written approval. The Recipient shall not use the Material or any substance that is replicated or derived thereof for any commercial or profit-generating purpose, or in the conduct of research that is subject to consulting, licensing or other similar legal or commercial obligations with other institutions, corporations or business entities includingentities, but not limited to, use in drug screening, drug evaluation, assay development, or identifying drug targets for commercial purposes without the unless EMBL provides its prior written consent of EMBLconsent. 2.3 After conclusion of the studies using according Annex 1 on the Material as defined in Annex 1 or at the expiry or termination of this MTA, whichever occurs first, the Recipient shall, at the discretion of the EMBL, either destroy or return to the EMBL the remaining Material and Modifications incorporating the Material. Upon request, the Recipient shall inform EMBL on the status of its research.

Use of the Material. 2.1 The Recipient shall use the Material in compliance with all laws and regulations applicable to such Material in the Recipient's place and country, including guidelines for work with recombinant DNA. The Material being experimental in nature must not be used in humans or animals unless -where - where applicable -explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals. 2.2 Nothing in this agreement MTA shall be construed as granting any license under any intellectual property right vested into EMBL or any right to use the Material or any EMBL information other than herein expressly specified. The Material shall be used exclusively for the purposes described in Annex 1. It must not be released to any person other than the Recipient's Researcher/s Researcher(s) named above and staff under their direct supervision who are bound by obligations not less strict than those set out herein. It shall be handled confidentially and nothing shall be forwarded to third parties only to the extent of unless with EMBL’s prior written approval. For any EMBL information or material that will be forwarded to third parties, the Recipient shall conclude confidentiality agreements with such third parties and they shall be bound by obligations not less strict than those set out in this MTA. The Recipient shall not use the Material or any substance that is replicated or derived thereof for any commercial or profit-generating purpose, or in the conduct of research that is subject to consulting, licensing or other similar legal or commercial obligations with other institutions, corporations or business entities including, but not limited to, use in drug screening, drug evaluation, assay development, or identifying drug targets for commercial purposes without the prior written consent of EMBL. 2.3 After conclusion of the studies using the Material as defined in Annex 1 or at the expiry of this MTA, whichever occurs first, the Recipient shall, at the discretion of the EMBL, either promptly destroy or return to the EMBL the remaining Material and Modifications incorporating the Material. All of EMBL's Material which is stored in electronic form shall be erased from the computer systems (to the extent possible). Upon request, within a period of thirty (30) days, the Recipient shall inform EMBL on the status of its research.

Use of the Material. 2.1 2.1. The Recipient represents and warrants that it shall only use the Material for the purpose of the Project in order to make the research specifically described in Annex 2 to this Agreement. 2.2. The Recipient agrees that it shall not be entitled to use, perform tests and / or carry out any other analysis of the Material nor any of its analogs, derivatives, synthesis or mixture of compounds for purposes not described in Annex 2, by itself or through third parties. The Recipient agrees not to make, develop, use, carry out tests and / or analyze the Material in any way for commercial purposes. 2.3. The Material shall not be used in research under consulting or license agreements of the Recipient or its scientific and / or employees with individuals, companies or other institutions not bound by this Agreement, without the prior written consent of the Provider. 2.4. The Recipient represents and warrants that it will use the Material in compliance with all applicable laws and regulations applicable to such Material in the Recipient's place and countryregulations, including guidelines for work with recombinant DNAbut not limited to health legislation relating to research involving the use of animals. The Parties agree that the Material being experimental in nature must not be used in humans or animals unless -where applicable -explicitly admitted by an ethics committee or regulations on the treatment of laboratory animalsSHALL NOT BE USED IN HUMANS. 2.2 Nothing in this agreement shall be construed as granting any license under any intellectual property right vested into EMBL or any right to use the Material or any EMBL information other than herein expressly specified2.5. The Material shall be stored and used exclusively for only at the purposes described in Annex 1. It must premises of the Recipient who undertakes not be released to any person other than change the Recipient's Researcher/s named above and staff under their direct supervision who are bound by obligations not less strict than those set out herein. It shall be handled confidentially and forwarded to third parties only to the extent location of EMBL’s prior written approval. The Recipient shall not use the Material or any substance that is replicated or derived thereof for any commercial or profit-generating purpose, or in the conduct custody of research that is subject to consulting, licensing or other similar legal or commercial obligations with other institutions, corporations or business entities including, but not limited to, use in drug screening, drug evaluation, assay development, or identifying drug targets for commercial purposes the same without the prior written consent of EMBL. 2.3 After conclusion of the studies using Provider. The Recipient also undertakes to limit access to the Material as defined to those of its employees taking part in Annex 1 or at the expiry Project who require access to the Material for the fulfillment of their responsibilities hereunder. In this MTA, whichever occurs firstregard, the Recipient shall, at ensures that all of its employees having access to Material shall comply with the discretion provisions of this Agreement. 2.6. This Agreement does not restrict the right of the EMBLProvider to transfer, either destroy deliver or return distribute the Material to third parties for commercial purposes or not, or to continue their own research and development of the Materials. 2.7. The present Agreement does not restrict the right of the Provider to publish, disclose or communicate information related to the EMBL Material. 2.8. The Recipient acknowledges that the remaining Provider does not grant any license to commercial use of the Material and Modifications incorporating the Material. Upon request, the Recipient shall inform EMBL that it may grant licenses to third parties for commercial purposes on the status of its researchan exclusive or non‐exclusive basis.